Henry Schein, Inc. (NASDAQ:HSIC) Shares Bought by National Bank of Canada FI

National Bank of Canada FI increased its position in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 1,124.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 535,950 shares of the company's stock after buying an additional 492,181 shares during the quarter. National Bank of Canada FI owned about 0.43% of Henry Schein worth $39,071,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Cromwell Holdings LLC grew its position in shares of Henry Schein by 93.4% during the third quarter. Cromwell Holdings LLC now owns 352 shares of the company's stock worth $26,000 after acquiring an additional 170 shares during the last quarter. Summit Securities Group LLC acquired a new position in Henry Schein in the second quarter valued at $31,000. Blue Trust Inc. raised its holdings in shares of Henry Schein by 104.2% in the second quarter. Blue Trust Inc. now owns 931 shares of the company's stock valued at $60,000 after buying an additional 475 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Henry Schein by 58.9% during the third quarter. Farther Finance Advisors LLC now owns 933 shares of the company's stock worth $68,000 after buying an additional 346 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its stake in shares of Henry Schein by 282.1% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,490 shares of the company's stock worth $109,000 after buying an additional 1,100 shares during the period. Institutional investors and hedge funds own 96.62% of the company's stock.

Henry Schein Price Performance

HSIC stock traded up $1.98 during trading on Monday, reaching $74.98. 1,728,313 shares of the company were exchanged, compared to its average volume of 1,400,268. Henry Schein, Inc. has a 52-week low of $63.67 and a 52-week high of $82.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The company has a market cap of $9.35 billion, a P/E ratio of 30.86, a PEG ratio of 2.09 and a beta of 0.87. The stock's 50 day moving average price is $71.83 and its 200 day moving average price is $69.92.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.05. The business had revenue of $3.17 billion for the quarter, compared to analysts' expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company's revenue was up .4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.32 EPS. As a group, analysts predict that Henry Schein, Inc. will post 4.78 earnings per share for the current fiscal year.

Insider Transactions at Henry Schein

In other Henry Schein news, COO Michael S. Ettinger sold 12,240 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the sale, the chief operating officer now owns 87,706 shares in the company, valued at approximately $6,577,950. This represents a 12.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.14% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on HSIC shares. Evercore ISI upped their price objective on Henry Schein from $70.00 to $74.00 and gave the company an "in-line" rating in a research note on Tuesday, October 8th. Barrington Research restated an "outperform" rating and set a $82.00 price target on shares of Henry Schein in a research note on Wednesday, November 6th. StockNews.com raised Henry Schein from a "sell" rating to a "hold" rating in a report on Thursday, November 7th. Mizuho began coverage on shares of Henry Schein in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $75.00 price objective on the stock. Finally, JPMorgan Chase & Co. reduced their target price on shares of Henry Schein from $88.00 to $80.00 and set an "overweight" rating for the company in a research note on Monday, August 12th. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $78.89.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.